High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer

被引:8
作者
Mohamed, Amr [1 ]
Jiang, Renjian [2 ]
Philip, Philip A. [3 ]
Diab, Maria [4 ]
Behera, Madhusmita [4 ]
Wu, Christina [4 ]
Alese, Olatunji [4 ]
Shaib, Walid L. [4 ]
Gaines, Tyra M. [4 ]
Balch, Glen G. [5 ]
El-Rayes, Bassel F. [4 ]
Akce, Mehmet [4 ]
机构
[1] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA
[2] Emory Univ, Winship Canc Inst, Winship Res Informat Shared Resource, Atlanta, GA 30322 USA
[3] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Dept Surg, Div Colorectal Surg, Atlanta, GA 30322 USA
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
基金
美国国家卫生研究院;
关键词
high risk; stage II; adjuvant chemotherapy; colon; cancer; DNA MISMATCH REPAIR; SURGICAL ADJUVANT BREAST; IMPROVED SURVIVAL; CHEMOTHERAPY; FLUOROURACIL; LEUCOVORIN; MANAGEMENT; CARCINOMA; EFFICACY; THERAPY;
D O I
10.3389/fonc.2021.755113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background High-risk features, such as T4 disease, bowel obstruction, poorly/undifferentiated histology, lymphovascular, perineural invasion, and <12 lymph nodes sampled, indicate poor prognosis and define high-risk stage II disease in proficient mismatch repair stage II colon cancer (CC). The prognostic role of high-risk features in dMMR/MSI-H stage II CC is unknown. Similarly, the role of adjuvant therapy in high-risk stage II CC with dMMR/MSI-H (>= 1 high-risk feature) has not been studied in prospective trials. The aim of this analysis of the National Cancer Database is to evaluate the prognostic value of high-risk features in stage II dMMR/MSI-H CC.</p> Methods Univariate (UVA) and multivariate (MVA) Cox proportional hazards (Cox-PH) models were built to assess the association between clinical and demographic characteristics and overall survival. Kaplan-Meier survival curves were generated with log-rank tests to evaluate the association between adjuvant chemotherapy in high-risk and low-risk cohorts separately.</p> Results A total of 2,293 stage II CC patients have dMMR/MSI-H; of those, 29.5% (n = 676) had high-risk features. The high-risk dMMR/MSI-H patients had worse overall survival [5-year survival and 95%CI, 73.2% (67.3-78.1%) vs. 80.3% (76.7-83.5%), p = 0.0001]. In patients with stage II dMMR/MSI-H CC, the high-risk features were associated with shorter overall survival (OS) along with male sex, positive carcinoembryonic antigen, Charlson-Deyo score >1, and older age. Adjuvant chemotherapy administration was associated with better OS, regardless of the high-risk features in dMMR/MSI-H (log-rank test, p = 0.001) or not (p = 0.0006). When stratified by age, the benefit of chemotherapy was evident only in patients age >= 65 with high-risk features.</p> Conclusion High-risk features are prognostic in the setting of dMMR/MSI-H stage II CC. Adjuvant chemotherapy may improve survival specifically in patients >= 65 years and with high-risk features.</p>
引用
收藏
页数:8
相关论文
共 29 条
  • [1] Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
    Andre, Thierry
    de Gramont, Armand
    Vernerey, Dewi
    Chibaudel, Benoist
    Bonnetain, Franck
    Tijeras-Raballand, Annemilai
    Scriva, Aurelie
    Hickish, Tamas
    Tabernero, Josep
    Van Laethem, Jean Luc
    Banzi, Maria
    Maartense, Eduard
    Shmueli, Einat
    Carlsson, Goran U.
    Scheithauer, Werner
    Papamichael, Demetris
    Moeehler, Marcus
    Landolfi, Stefania
    Demetter, Pieter
    Colote, Soudhir
    Tournigand, Christophe
    Louvet, Christophe
    Duval, Alex
    Flejou, Jean-Francois
    de Gramont, Aimery
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (35) : 4176 - +
  • [2] PERFORATION OF COLONIC NEOPLASMS - A REVIEW OF 36 CASES
    BADIA, JM
    SITGESSERRA, A
    PLA, J
    RAGUE, JM
    ROQUETA, F
    SITGESCREUS, A
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 1987, 2 (04) : 187 - 189
  • [3] Bastos Diogo Assed, 2010, Ther Adv Med Oncol, V2, P261, DOI 10.1177/1758834010367905
  • [4] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
    Benson, AB
    Schrag, D
    Somerfield, MR
    Cohen, AM
    Figueredo, AT
    Flynn, PJ
    Krzyzanowska, MK
    Maroun, J
    McAllister, P
    Van Cutsem, E
    Brouwers, M
    Charette, M
    Haller, DG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3408 - 3419
  • [5] Adjuvant Chemotherapy Is Associated With Improved Survival in Patients With Stage II Colon Cancer
    Casadaban, Leigh
    Rauscher, Garth
    Aklilu, Mebea
    Villenes, Dana
    Freels, Sally
    Maker, Ajay V.
    [J]. CANCER, 2016, 122 (21) : 3277 - 3287
  • [6] Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
    Cohen, R.
    Buhard, O.
    Cervera, P.
    Hain, E.
    Dumont, S.
    Bardier, A.
    Bachet, J. -B.
    Gornet, J. -M.
    Lopez-Trabada, D.
    Dumont, S.
    Kaci, R.
    Bertheau, P.
    Renaud, F.
    Bibeau, F.
    Parc, Y.
    Vernerey, D.
    Duval, A.
    Svrcek, M.
    Andre, Thierry
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 86 : 266 - 274
  • [7] HENSON DE, 1992, CANCER, V70, P1493, DOI 10.1002/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO
  • [8] 2-U
  • [9] Cancer Statistics, 2009
    Jemal, Ahmedin
    Siegel, Rebecca
    Ward, Elizabeth
    Hao, Yongping
    Xu, Jiaquan
    Thun, Michael J.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2009, 59 (04) : 225 - 249
  • [10] Implications of mismatch repair-deficient status on management of early stage colorectal cancer
    Kawakami, Hisato
    Zaanan, Aziz
    Sinicrope, Frank A.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (06) : 676 - 684